title: Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
authors.affiliation: Service de Pharmacologie, Toxicologie, Pharmacovigilance Hôpital Dupuytren, 87042 Limoges, France.
authors.forename: M L
authors.initials: ML
authors.lastname: Laroche
authors.forename: L
authors.initials: L
authors.lastname: Merle
mesh_terms: D000368:Aged; D017277:Drug Approval; D016568:Drugs, Generic / Q000009:adverse effects* / Q000592:standards*; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000009:adverse effects*; D010627:Phenethylamines / Q000009:adverse effects*
chemical_list: D016568:Drugs, Generic; D010276:Parasympatholytics; D010627:Phenethylamines; C005096:mebeverine